Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
NOX Inhibitors: From Bench to Naxibs to Bedside
Mahmoud H. Elbatreek
*
, Hermann Mucke
,
Harald H.H.W. Schmidt
*
Corresponding author for this work
MHeNs - Neuroscience
Pharmacology and Personalised Medicine
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
Academic
630
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'NOX Inhibitors: From Bench to Naxibs to Bedside'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Reactive Oxygen Species
100%
NOX Inhibitors
100%
NOX1
30%
NADPH Oxidase 4 (NOX4)
30%
NOX5
30%
NADPH Oxidase 2 (NOX2)
20%
NADPH Oxidase
20%
Antioxidant
20%
Reactive Oxygen Species Signaling
20%
Clinically Significant
10%
Clinical Trials
10%
Pathophysiology
10%
Family Members
10%
Overproduction
10%
Disease-associated
10%
Biological Function
10%
Putative Drug Targets
10%
Genetic Deficiency
10%
Hydrogen Peroxide
10%
Disease States
10%
Superoxide
10%
Signaling Molecules
10%
New Therapeutics
10%
First-in-class
10%
NADPH Oxidase Inhibitor
10%
GKT137831
10%
Non-selective
10%
Gene Therapy
10%
Subcellular Location
10%
Therapeutic Class
10%
Cellular Signaling
10%
Metabolic Products
10%
Chronic Granulomatous Disease
10%
Physiological Characters
10%
Gp91phox
10%
Reactive Oxygen Species Scavenging
10%
Scavenging Effect
10%
DUOX1
10%
Setanaxib
10%
Nox Family
10%
Neutralizer
10%
INIS
oxygen
100%
diseases
46%
oxidases
23%
reviews
15%
antioxidants
15%
validation
7%
applications
7%
rats
7%
drugs
7%
damage
7%
clinical trials
7%
mice
7%
molecules
7%
genetics
7%
atherosclerosis
7%
reflection
7%
WHO
7%
biological functions
7%
hydrogen peroxide
7%
by-products
7%
scavenging
7%
gene therapy
7%
Immunology and Microbiology
NADPH Oxidase
100%
Superoxide
33%
Atherosclerosis
33%
Hydrogen Peroxide
33%
Biological Functions
33%
Chronic Granulomatous Disease
33%
Target Organism
33%
Medicine and Dentistry
Reactive Oxygen Species
100%
Diseases
38%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
23%
Antioxidant
15%
Hydrogen Peroxide
7%
Pathophysiology
7%
Superoxide
7%
Clinical Trial
7%
Atherosclerosis
7%
Chronic Granulomatous Disease
7%
Signaling Molecule
7%
Gene Therapy
7%
Biological Functions
7%
2 (2 Chlorophenyl) 4 [3 (Dimethylamino)phenyl] 5 Methyl 1h pyrazolo[4,3 C]pyridine 3,6(2h,5h) Dione
7%
Oxidoreductase Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Reactive Oxygen Metabolite
100%
Diseases
38%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
23%
Antioxidant
15%
Pathophysiology
7%
Superoxide
7%
Clinical Trial
7%
Atherosclerosis
7%
Hydrogen Peroxide
7%
Chronic Granulomatous Disease
7%
2 (2 Chlorophenyl) 4 [3 (Dimethylamino)phenyl] 5 Methyl 1h pyrazolo[4,3 C]pyridine 3,6(2h,5h) Dione
7%
Oxidoreductase Inhibitor
7%
Neuroscience
Reactive Oxygen Species
100%
NADPH Oxidase
23%
Antioxidant
15%
Hydrogen Peroxide
7%
Cell Signaling
7%